John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

Some highlights of the eJFHOD congress 2020 in digestive oncology Volume 27, supplement 3, Octobre 2020

Figures

  • Figure 1
  • Figure 2
  • Figure 3
Author
CHU de Nantes, Institut des Maladies de l’Appareil Digestif, 1 place Alexis Ricordeau, 44000 Nantes
* Correspondance

There was a lot of news in digestive oncology at eJFHOD 2020 and this report is only a selection.. Following the results of the BEACON CCR study, a new European Marketing Authorization has been issued for encorafenib combined with cetuximab in colorectal cancers with BRAF V600E mutation in the second line. Circulating tumor DNA and the presence of tumor deposits are important prognostic factors in localized colorectal cancers. There is growing evidence for the role of chekpoint inhibitors in esophageal cancer. Personalized medicine is promising in biliary tract cancers whereas Folfirinox fails in the first-line AMEBICA phase II trial. Finally, the atezolizumab-bevacizumab combination is a new first-line standard with temporary authorization for cohort use since July 20, 2020, and future clinical trials evaluating selective intra-arterial radiotherapy should include personalized dosimetry.